June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Canadian Glaucoma Study 4: Neuroretinal Rim Area Change in Patients with Visual Field-based Endpoints and Interventions
Author Affiliations & Notes
  • Rizwan Malik
    Ophthalmology and Visual Sciences, Dalhousie University, Halifax, NS, Canada
    NIHR Biomedical Research Centre for Ophthalmology at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom
  • Neil O'Leary
    Ophthalmology and Visual Sciences, Dalhousie University, Halifax, NS, Canada
    Centre for Biostatistics, Institute of Population Health, School of Medicine, University of Manchester, Manchester, United Kingdom
  • Frederick Mikelberg
    Ophthalmology and Visual Sciences, University of British Columbia, Vancouver, BC, Canada
  • Gordon Balazsi
    Ophthalmology, McGill University, Montreal, QC, Canada
  • Raymond LeBlanc
    Ophthalmology and Visual Sciences, Dalhousie University, Halifax, NS, Canada
  • Mark Lesk
    Université de Montréal, Montreal, QC, Canada
  • Marcelo Nicolela
    Ophthalmology and Visual Sciences, Dalhousie University, Halifax, NS, Canada
  • Graham Trope
    Ophthalmology and Visual Sciences, University of Toronto, Toronto, ON, Canada
  • Balwantray Chauhan
    Ophthalmology and Visual Sciences, Dalhousie University, Halifax, NS, Canada
  • Footnotes
    Commercial Relationships Rizwan Malik, NIHR Moorfields Biomedical Research Centre (F), Special Trustees of Moorfields Eye Hospital (F); Neil O'Leary, None; Frederick Mikelberg, None; Gordon Balazsi, None; Raymond LeBlanc, None; Mark Lesk, None; Marcelo Nicolela, Allergan Inc (F), Alcon (F); Graham Trope, sensimed (F); Balwantray Chauhan, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 2620. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Rizwan Malik, Neil O'Leary, Frederick Mikelberg, Gordon Balazsi, Raymond LeBlanc, Mark Lesk, Marcelo Nicolela, Graham Trope, Balwantray Chauhan, ; Canadian Glaucoma Study 4: Neuroretinal Rim Area Change in Patients with Visual Field-based Endpoints and Interventions. Invest. Ophthalmol. Vis. Sci. 2013;54(15):2620.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

(1) To compare rates of neuroretinal rim area (RA) change in patients with and without a visual field (VF) endpoint in the Canadian Glaucoma Study (CGS). (2) To determine whether IOP intervention after the VF endpoint had an impact on RA change.

 
Methods
 

Patients were treated to achieve a target IOP and examined at 4-month intervals with standard automated perimetry and confocal scanning laser tomography (CSLT). Patients reaching a VF endpoint defined by repeatable progression based on total deviation change probability analysis underwent an additional ≥ 20% IOP reduction (Canadian Glaucoma Study Group. Canadian Glaucoma Study I. Can J Ophthalmol. 2006; 41: 566-75). RA rates were computed with robust linear regression only when ≥ 4 examinations were available and compared for patients with and without a VF endpoint. For patients with endpoints, the change in RA rate was computed (RA rate post-intervention - RA rate pre-intervention).

 
Results
 

Of the 258 enrolled patients, 206 (80%) had sufficient follow-up to compute RA rates. The median (interquartile range, IQR) baseline age, follow-up and number of CSLT examinations was 68 (58, 75) years, 6 (5, 7) years, and 15 (12, 19) respectively. The median (IQR) RA rate prior to a VF endpoint of -14 (-32, 11) x 10-3 mm2/ year (n=59) was significantly worse (P=0.02, see figure), compared to that in patients with no endpoint: -5 (-14, 5) x 10-3 mm2/year (n=147). In 43 patients with sufficient follow-up before and after IOP-lowering intervention, the median change (95% CI) in RA rate was 8 (-10, 24) x 10-3 mm2/year.

 
Conclusions
 

Prior to the VF endpoint, patients with VF progression had a median RA rate that was nearly 3 times worse compared to those without progression. After the endpoint, IOP intervention did not have a statistically significant impact on the subsequent RA rate.

 
 
Distribution of RA rates prior to the first VF endpoint, in patients with and without a VF endpoint.
 
Distribution of RA rates prior to the first VF endpoint, in patients with and without a VF endpoint.
 
Keywords: 552 imaging methods (CT, FA, ICG, MRI, OCT, RTA, SLO, ultrasound) • 466 clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • 627 optic disc  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×